BALAXI PHARMACEUTICALS LIMITED
Balaxi Pharmaceuticals Limited engages in the international wholesale distribution of pharmaceuticals, builders hardware, and FMCG products in Africa, the Caribbean Islands, and Latin America. The company offers pharmaceutical products across various therapeutic areas that mainly treats antibiotics, analgesic, anti-malaria, and others. It also provides biscuits and toothpastes. The company was fo… Read more
BALAXI PHARMACEUTICALS LIMITED (BALAXI) - Total Liabilities
Latest total liabilities as of September 2025: ₹844.30 Million INR
Based on the latest financial reports, BALAXI PHARMACEUTICALS LIMITED (BALAXI) has total liabilities worth ₹844.30 Million INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
BALAXI PHARMACEUTICALS LIMITED - Total Liabilities Trend (2013–2025)
This chart illustrates how BALAXI PHARMACEUTICALS LIMITED's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
BALAXI PHARMACEUTICALS LIMITED Competitors by Total Liabilities
The table below lists competitors of BALAXI PHARMACEUTICALS LIMITED ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Alien Metals Ltd
PINK:ASLRF
|
USA | $1.71 Million |
|
C2C Gold Corp
OTCQB:CTCGF
|
USA | $202.85K |
|
DistIT AB (publ)
ST:DIST
|
Sweden | Skr399.20 Million |
|
IMAGIS Co. Ltd
KQ:115610
|
Korea | ₩1.82 Billion |
|
Cubtek Inc.
TWO:2252
|
Taiwan | NT$308.84 Million |
|
Western Bulk Chartering AS
PINK:WSSTF
|
USA | $57.00 Million |
|
Hemostemix Inc
OTCQB:HMTXF
|
USA | $4.80 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down BALAXI PHARMACEUTICALS LIMITED's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BALAXI PHARMACEUTICALS LIMITED's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BALAXI PHARMACEUTICALS LIMITED (2013–2025)
The table below shows the annual total liabilities of BALAXI PHARMACEUTICALS LIMITED from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹786.06 Million | +37.96% |
| 2024-03-31 | ₹569.79 Million | +0.33% |
| 2023-03-31 | ₹567.89 Million | -10.29% |
| 2022-03-31 | ₹633.07 Million | +82.44% |
| 2021-03-31 | ₹347.00 Million | +321.88% |
| 2020-03-31 | ₹82.25 Million | +217.90% |
| 2019-03-31 | ₹25.87 Million | +1859.33% |
| 2018-03-31 | ₹1.32 Million | -39.26% |
| 2017-03-31 | ₹2.17 Million | +5061.73% |
| 2016-03-31 | ₹42.12K | -7.73% |
| 2015-03-31 | ₹45.65K | -98.92% |
| 2014-03-31 | ₹4.24 Million | -12.73% |
| 2013-03-31 | ₹4.86 Million | -- |